Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The qinghaosu (artemisinin) group of drugs is the most important new class of antimalarials developed in the last fifty years. Although there has been no clinical evidence of neurotoxicity, an unusual pattern of damage to specific brain-stem nuclei has been reported in experimental animals receiving high doses of arteether or artemether. Detailed clinical examinations, audiometry, and brain stem auditory evoked potentials (BSAEPs) were assessed in 242 Vietnamese subjects who had previously received up to 21 antimalarial treatment courses of artemisinin or artesunate alone and 108 controls from the same location who had not received these drugs. There was no evidence of a drug effect on the clinical or neurophysiological parameters assessed. In this population there was no clinical or neurophysiological evidence of brain-stem toxicity that could be attributed to exposure to artemisinin or artesunate.

Type

Journal article

Journal

Am J Trop Med Hyg

Publication Date

07/2000

Volume

63

Pages

48 - 55

Keywords

Adolescent, Adult, Aged, Antimalarials, Artemisinins, Case-Control Studies, Child, Child, Preschool, Drug Administration Schedule, Evoked Potentials, Auditory, Brain Stem, Female, Humans, Infant, Malaria, Male, Mefloquine, Middle Aged, Neurologic Examination, Sesquiterpenes, Vietnam